(Q35739717)

10 August 2017

1 reference

title

Gefitinib, a novel, orally administered agent for the treatment of cancer (English)

1 reference

10 August 2017

1 reference

ChEBI release 2020-05-28

M Ranson

1

1 reference

10 August 2017

S Wardell

series ordinal

2

1 reference

10 August 2017

publication date

1 April 2004

1 reference

Journal of Clinical Pharmacy and Therapeutics

10 August 2017

published in

1 reference

10 August 2017

volume

29

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

95-103

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

Prestin, the motor protein of outer hair cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

Mechanoelectrical and Voltage-Gated Ion Channels in Mammalian Vestibular Hair Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00543.X

10.1111/J.1365-2710.2004.00543.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference